Compound FLZ attenuates neuroinflammation through inhibiting Src/PTEN/Akt signaling pathway.

Compound FLZ has neuroprotective effects on Parkinson's disease (PD), while the precise mechanism remains unclear. In this study, we found that FLZ decreased PTEN/Akt activity in LPS-challenged BV2 cells. Neuroinflammatory responses suppressed by FLZ were abolished when PTEN or Src was inhibited. Additionally, FLZ weakened the interactions of Src and PTEN, and attenuated Src phosphorylation once PETN was inhibited, but failed to decrease PTEN phosphorylation when Src was silenced. Eventually, we elaborated that FLZ bound to Src directly and inhibited its activity. Collectively, FLZ attenuated neuroinflammation through inhibiting Src/PTEN/Akt pathway, paving the way for clinical use of FLZ to treat PD.